Burlington, LLS Join Forces for 12th Straight Year

The Leukemia and Lymphoma Society (LLS) has already begun its annual back-to-school fundraiser through one of the organization's biggest corporate partners, Burlington Coat Factory.

Through Oct. 19, Burlington customers can purchase a paper balloon at checkout for a minimum donation of $1 – with all proceeds going to the LLS to benefit blood cancer patients.

Customers then join in on one of almost 200 evening walks nationwide devoted to the "Light the Night" campaign carrying one of those balloons. "Light the Night" has been an incredible boost in the fight against blood cancers, helping the LLS to invest more than $875 million towards research to discover and deliver breakthrough cancer treatments that are saving lives today.

This will be the 12th consecutive year that Burlington will serve as the number one National Corporate Partner and Honored Friend of the "Light the Night" Campaign. Over the previous 11 years, Burlington has contributed to the LLS mission by raising more than $16 million to help fund innovative cancer research and patient services.

Over the last year alone, more than 3 million Burlington customers donated to the LLS cause at more than 500 store locations.

As the world's largest voluntary health agency dedicated to curing blood cancer, the LLS is uniquely positioned to bring positive change to the cancer landscape, with their laser focus on cures and access to lifesaving treatments, and to improving the quality of life of patients and their families.

Source: LLS

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap